Prostate Cancer

View All

Cancer
Snippet

HOA Puts into Operation of Updated CyberKnife Version Cancer patients now have a solid reason to cheer, as US-based Hematology-Oncology Associates (HOA) lately came up with the new CyberKnife (CK) and replaced their original CyberKnife with an updated that is even more precise, fast and effective, and known as the ...

Find More

Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces

Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...

Find More

Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds

Novartis, slammed by Korean scandal, tweaks its ethics, compliance policies Rocked by a corruption scandal in Korea and facing a kickbacks probe in Greece, Novartis says it's strengthening and simplifying its global ethics and compliance approach. The Swiss drug giant is aiming to shift from policing to coaching, wi...

Find More

Prostate Cancer: Metastases leading to increased incidence in the USA

A study, Analysis of Surveillance, Epidemiology, and End Results (SEER), has shed light on the increased prevalence of incidence of distant metastasis at diagnosis in men aged ≥75 years with prostate cancer. This increase is most probably the result of a recommendation provided by the US Preventative Services Task F...

Find More

Delveinsight
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...

Find More